✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Betta Pharmaceuticals Co., Ltd.

Common Name
Betta Pharmaceuticals
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,785
Ticker
300558
Exchange
Shenzhen Stock Exchange
Description
Betta Pharmaceuticals Co. Ltd. is a biopharmaceutical company based in China, specializing in research, development, and commercialization of innovative drugs, primarily targeting cancer treatments. T...

Betta Pharmaceuticals's GHG Emissions Data Preview

In 2025, Betta Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Betta Pharmaceuticals has also provided a category-level breakdown for 3 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2025202420232022-2019
Total Scope 1
1,267.74a
2,023.91a
2,282.73a
Total Scope 2
Unspecified Calculation Method
11,171.77a
8,459.8a
10,876.99a
Total Scope 3
151,301.66a
114,778.61a
121,112.9a
Total Scope 1 Revenue Intensity (tCO2e/$M)
2.459a
5.1075a
6.6051a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=300558&reporting_period=2025"

Verified Sources Behind Betta Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Betta Pharmaceuticals's Sustainability Report 2025
a. Betta Pharmaceuticals's Sustainability Report 2025

Insights into Betta Pharmaceuticals's Operational Emissions

In 2025, the total operational greenhouse gas (GHG) emissions of Betta Pharmaceuticals amounted to 12,439.51 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2024, the total operational greenhouse gas (GHG) emissions of Betta Pharmaceuticals increased by 18.66%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Betta Pharmaceuticals's Scope 1 Emissions Over Time

20232024202506001.2 k1.8 k2.4 ktCO2e-11%-37%
  • Total Scope 1
  • Year-over-Year Change

What are Betta Pharmaceuticals's Scope 1 emissions?

In 2025, the total Scope 1 emissions of Betta Pharmaceuticals were 1,267.74 metric tons of CO₂ equivalent (tCO₂e).a

Has Betta Pharmaceuticals reduced its Scope 1 emissions over time?

Since 2023, Betta Pharmaceuticals's Scope 1 emissions have decreased by 44.46%, reflecting a declining long-term trend in Scope 1 emissions over time.a

Compared to the previous year (2024), Betta Pharmaceuticals's Scope 1 emissions decreased by 37.36%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Betta Pharmaceuticals's Scope 2 emissions?

In 2025, Betta Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 11,171.77 tCO₂e without specifying the calculation method.a

Has Betta Pharmaceuticals reduced its Scope 2 emissions over time?

Since 2023, Betta Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Betta Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a

Compared to the previous year (2024), Betta Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) rose by 32.06% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya

What methodology does Betta Pharmaceuticals use for Scope 2 reporting?

In 2025, Betta Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a

Betta Pharmaceuticals's Scope 2 Emissions Over Time

20232024202503 k6 k9 k12 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Betta Pharmaceuticals's Value Chain Emissions

In 2025, Betta Pharmaceuticals reported 151,301.66 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2025 disclosure of Betta Pharmaceuticals includes a breakdown across 3 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Betta Pharmaceuticals's Scope 3 Emissions Over Time

202320242025040 k80 k120 k160 ktCO2e-5%+32%
  • Total Scope 3
  • Year-over-Year Change

What are Betta Pharmaceuticals's Scope 3 emissions?

In 2025, Betta Pharmaceuticals reported total Scope 3 emissions of 151,301.66 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Betta Pharmaceuticals reduced its Scope 3 emissions over time?

Since 2023, Betta Pharmaceuticals's Scope 3 emissions have increased by 24.93%, reflecting a rising long-term trend in Scope 3 emissions over time.a

Compared to the previous year (2024), Betta Pharmaceuticals's Scope 3 emissions increased by 31.82%, suggesting that the company faced challenges in reducing emissions across its value chain.a

What categories of Scope 3 emissions does Betta Pharmaceuticals disclose?

In 2025, Betta Pharmaceuticals reported emissions for 3 out of the 15 Scope 3 categories defined by the GHG Protocol.a

The limited disclosure restricts visibility into specific emission sources across the company's value chain.

What are the main sources of Betta Pharmaceuticals's Scope 3 emissions?

In 2025, the largest contributors to Betta Pharmaceuticals's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 147,467.04 tCO₂e (97.47%)
  • Waste Generated in Operations (Cat. 5): 2,524.16 tCO₂e (1.67%)
  • Employee Commuting (Cat. 7): 1,310.46 tCO₂e (0.87%)

Betta Pharmaceuticals's Scope 3 Emissions by Categories

Purchased Goods andServices (Cat. 1)(97.5%)Waste Generated inOperations (Cat. 5)(1.7%)

Insights into Betta Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Betta Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 1,267.74 tCO₂e and total revenues of USD 516 millions. This translates into an emissions intensity of 2.46 tCO₂e per millions USD.a

Betta Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers

2002,00010,000100,0001,000,000Scope 1 Emissions (tCO2e)502001,0002,00010,000Revenues (Millions of USD)Yunnan Baiyao GroupYear: 2025Scope 1: 34,719 tCO2eRevenue: $M 5,883Scope 1 Intensity: 5.90 tCO2e/$MHansoh Pharmaceutical GroupYear: 2025Scope 1: 11,834 tCO2eRevenue: $M 2,147Scope 1 Intensity: 5.51 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2025Scope 1: 54,874 tCO2eRevenue: $M 4,518Scope 1 Intensity: 12.15 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 864Scope 1 Intensity: 12.44 tCO2e/$MCanSino BiologicsYear: 2025Scope 1: 2,121 tCO2eRevenue: $M 151Scope 1 Intensity: 14.02 tCO2e/$MJoincareYear: 2025Scope 1: 219,583 tCO2eRevenue: $M 2,173Scope 1 Intensity: 101.03 tCO2e/$MCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MApeloa PharmaceuticalYear: 2025Scope 1: 75,760 tCO2eRevenue: $M 1,397Scope 1 Intensity: 54.21 tCO2e/$MZhejiang Huahai PharmaceuticalYear: 2024Scope 1: 58,691 tCO2eRevenue: $M 1,308Scope 1 Intensity: 44.86 tCO2e/$MLivzon Pharmaceutical GroupYear: 2025Scope 1: 175,562 tCO2eRevenue: $M 1,717Scope 1 Intensity: 102.25 tCO2e/$MDizal PharmaceuticalYear: 2025Scope 1: 887 tCO2eRevenue: $M 114Scope 1 Intensity: 7.75 tCO2e/$MChangchun High-TechYear: 2025Scope 1: 133,335 tCO2eRevenue: $M 1,726Scope 1 Intensity: 77.25 tCO2e/$MPorton Pharma SolutionsYear: 2025Scope 1: 9,489 tCO2eRevenue: $M 488Scope 1 Intensity: 19.43 tCO2e/$MDa Ren TangYear: 2025Scope 1: 3,870 tCO2eRevenue: $M 702Scope 1 Intensity: 5.51 tCO2e/$MShenzhen Salubris PharmaceuticalsYear: 2024Scope 1: 11,399 tCO2eRevenue: $M 550Scope 1 Intensity: 20.73 tCO2e/$MSichuan Biokin PharmaceuticalYear: 2025Scope 1: 8,090 tCO2eRevenue: $M 360Scope 1 Intensity: 22.48 tCO2e/$MSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 262Scope 1 Intensity: 174.19 tCO2e/$MConsun Pharmaceutical GroupYear: 2025Scope 1: 7,133 tCO2eRevenue: $M 488Scope 1 Intensity: 14.61 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2025Scope 1: 57,658 tCO2eRevenue: $M 787Scope 1 Intensity: 73.28 tCO2e/$MHepalinkYear: 2025Scope 1: 13,483 tCO2eRevenue: $M 777Scope 1 Intensity: 17.36 tCO2e/$MBioKangtaiYear: 2025Scope 1: 15,001 tCO2eRevenue: $M 382Scope 1 Intensity: 39.29 tCO2e/$MChengdu Kanghong Pharmaceutical GroupYear: 2025Scope 1: 11,555 tCO2eRevenue: $M 655Scope 1 Intensity: 17.64 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MBetta PharmaceuticalsYear: 2025Scope 1: 1,268 tCO2eRevenue: $M 516Scope 1 Intensity: 2.46 tCO2e/$M

How does Betta Pharmaceuticals's GHG emissions intensity compare to its peers?

In 2025, Betta Pharmaceuticals reported a Scope 1 emissions intensity of 2.46 tCO₂e per millions USD. Compared to the peer group median of 20.25, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Betta Pharmaceuticals rank on GHG emissions intensity within its industry?

In 2025, Betta Pharmaceuticals ranked 1 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Betta Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers.a

Insights into Betta Pharmaceuticals's Total Carbon Footprint

In 2025, Betta Pharmaceuticals reported a total carbon footprint of 163,741.17 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 30.72% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a

The largest contributor to Betta Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 92.4% of the company's total carbon footprint, followed by Scope 2 emissions at 6.82%.a

Want Full Access to Betta Pharmaceuticals's GHG Emissions Dataset?
Start 30-Day Free Trial